MUC16 and neoplasm: The pretreatment levels of CA-125 in NR versus R patients are not significantly different (P > 0.05; Fig. 2F), suggesting that the tumor burden is not a discriminating factor between NR and R patients and both groups entered the treatment with similar status of their disease.